Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX3330 in Patients With Advanced Solid Tumors
NCT03375086Phase 1Completed
- Sponsor
- Apexian Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APX3330 in solid tumor, sponsored by Apexian Pharmaceuticals. Primary endpoint: Treatment-Related Adverse Events at 12 months. Started Jan 2018; status: completed.
02
Drugs
APX3330
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03375086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375086.